{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:49:11Z","timestamp":1792622951386,"version":"4.5.0"},"reference-count":63,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["mSystems"],"published-print":{"date-parts":[[2025,9,23]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Hepatitis E virus (HEV) is a major cause of acute viral hepatitis in lower- and middle-income countries. HEV infection may lead to acute liver failure, chronic liver disease, and high mortality in pregnant women. Antiviral therapy is not a standard treatment for HEV patients. Computational biology tools promise to revolutionize the antiviral drug discovery. Here, we analyzed the transcriptome data of HEV-infected primary human hepatocyte cells through the connectivity map database and applied control theory on the functional network to identify antiviral targets against HEV. The above analyses predicted PKC\u03b2, PKB\/AKT, and CK1\u03b5 as potential antiviral targets against HEV. The antiviral function of PKB\/AKT and CK1\u03b5 was experimentally validated by using respective biochemical inhibitors in g3 (genotype 3)-HEV replicon and Huh7 cell-based model of g3 and g1-HEV infection. Furthermore, knockdown of CK1\u03b5 showed a similar effect. These data confirmed that CK1\u03b5 is an antiviral target for HEV. At present, there are no Food and Drug Administration (FDA)-approved drugs targeting CK1\u03b5. Etravirine is an FDA-approved non-nucleoside reverse transcriptase inhibitor drug, used for the treatment of AIDS patients. An\n                      <jats:italic toggle=\"yes\">in silico<\/jats:italic>\n                      study predicted Etravirine to be a potent inhibitor of CK1\u03b5. Our experiments revealed potent antiviral activity of Etravirine against HEV, which was mediated via its ability to inhibit the activity of CK1\u03b5. Taken together, the current study demonstrates that PKB\/AKT and CK1\u03b5 are bona fide antiviral targets for HEV and paves the way for repurposing Etravirine for the treatment of HEV-infected patients.\n                    <\/jats:p>\n                    <jats:sec>\n                      <jats:title>IMPORTANCE<\/jats:title>\n                      <jats:p>Antiviral treatment is not the standard care for acute viral hepatitis E patients. Unbiased identification of antiviral targets or large-scale screening of antiviral compounds against the hepatitis E virus (HEV) has not been reported. Here, a computational biology approach was followed to unbiasedly identify antiviral targets of HEV. Transcriptome data of HEV-infected primary human hepatocyte cells were analyzed to identify modulators of the network and generate directional networks. Network controllability analysis identified PKC\u03b2, PKB\/AKT, and CK1\u03b5 as potential antiviral targets against HEV. Antiviral function of PKB\/AKT and CK1\u03b5 was confirmed using cell-based models of genotype 1 (g1)- and g3-HEV infection. Further experiments demonstrated the antiviral activity of Etravirine against HEV, mediated via its ability to inhibit the CK1\u03b5 activity. Etravirine is a Food and Drug Administration-approved non-nucleoside reverse transcriptase inhibitor, used for the treatment of AIDS patients. This study reveals the potential of repurposing Etravirine for the treatment of HEV patients and illustrates the importance of computational biology in antiviral drug discovery.<\/jats:p>\n                    <\/jats:sec>\n                  <\/jats:sec>","DOI":"10.1128\/msystems.00438-25","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T15:09:26Z","timestamp":1755270566000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":1,"title":["Network controllability analysis reveals the antiviral potential of Etravirine against hepatitis E virus infection"],"prefix":"10.1128","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1773-2362","authenticated-orcid":false,"given":"Shabnam","family":"Ansari","sequence":"first","affiliation":[{"name":"Virology Laboratory, Center for Virus research, therapeutics and vaccines, Translational Health Science and Technology Institute, NCR Biotech Science Cluster","place":["Faridabad, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipanka Tanu","family":"Sarmah","sequence":"additional","affiliation":[{"name":"Complex analysis group, Computational and Mathematical Biology Center, Translational Health Science and Technology Institute, NCR Biotech Science Cluster","place":["Faridabad, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Verma","sequence":"additional","affiliation":[{"name":"Virology Laboratory, Center for Virus research, therapeutics and vaccines, Translational Health Science and Technology Institute, NCR Biotech Science Cluster","place":["Faridabad, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kannan","family":"Chandrasekar","sequence":"additional","affiliation":[{"name":"Virology Laboratory, Center for Virus research, therapeutics and vaccines, Translational Health Science and Technology Institute, NCR Biotech Science Cluster","place":["Faridabad, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Shalimar","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00t0ht588","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Gastroenterology, All India Institute of Medical Sciences","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baibaswata","family":"Nayak","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00t0ht588","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Gastroenterology, All India Institute of Medical Sciences","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5010-2799","authenticated-orcid":false,"given":"Samrat","family":"Chatterjee","sequence":"additional","affiliation":[{"name":"Complex analysis group, Computational and Mathematical Biology Center, Translational Health Science and Technology Institute, NCR Biotech Science Cluster","place":["Faridabad, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8435-3257","authenticated-orcid":true,"given":"Milan","family":"Surjit","sequence":"additional","affiliation":[{"name":"Virology Laboratory, Center for Virus research, therapeutics and vaccines, Translational Health Science and Technology Institute, NCR Biotech Science Cluster","place":["Faridabad, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.3390\/v13050909"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2017.150"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/gastro\/gov042"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.07.010"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.3390\/v15061389"},{"key":"e_1_3_4_7_2","unstructured":"World Health Organization. 2024. Hepatitis E. Retrieved Oct 2024."},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14912"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)90761-0"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2009.01101.x"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005521"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215246"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-153-2-201007200-00256"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.08.002"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2017.1358349"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.08.040"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.05.002"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.3390\/v14081778"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.3c05637"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/14756366.2023.2280500"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00705-017-3444-8"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-04449-3"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.02.036"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00705-023-05770-1"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2021.02.002"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00684-18"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00754-17"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.881595"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/msystems.00135-17"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2020.02.025"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-biodatasci-072018-021211"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature10011"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","unstructured":"Sarmah DT Paul A Berry U Surjit M Bairagi N Chatterjee S. 2023. BAG6 is a novel player in controlling nonalcoholic steatohepatitis: result from a comprehensive in-silico study. bioRxiv. doi:10.1101\/2023.05.04.539506","DOI":"10.1101\/2023.05.04.539506"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1912307117"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32833677ac"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1652"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00830-9"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27604"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph15010008"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.911764"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3395"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2017.01.005"},{"key":"e_1_3_4_43_2","unstructured":"U S Food and Drug Administration Drug Approvals and databases. 2021. FDA grants accelerated approval to umbralisib for marginal zone lymphoma and follicular lymphoma. FDA. Retrieved 05 Feb 2021."},{"key":"e_1_3_4_44_2","unstructured":"U S Food and Drug Administration Drug Approvals and databases. 2022. FDA withdrew its approval for the cancer medicine Ukoniq (umbralisib) due to safety concerns. FDA."},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.05.026"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-2738"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2018.4597"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1159\/000446447"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.18628"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.06.009"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1000017"},{"key":"e_1_3_4_52_2","unstructured":"U S Food and Drug Administration Drug Approvals and databases. 2023. FDA approves capivasertib with fulvestrant for breast cancer. FDA. Retrieved 16 Nov 2023."},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-13-231"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2016.12.010"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.25.7.2795-2807.2005"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1231499"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21176449"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C700070200"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","unstructured":"Lin S Chang P He J Coyaud E Pierce B Zhang Y. 2020. RNA helicase DDX3 interacts with the capsid protein of hepatitis E virus and plays an indispensable role in the viral replication. Life Sciences. doi:10.20944\/preprints202012.0557.v1","DOI":"10.20944\/preprints202012.0557.v1"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.7b00524"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.10.049"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1603992113"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.9.4838-4846.2004"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00146-12"}],"container-title":["mSystems"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/msystems.00438-25","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/msystems.00438-25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T13:01:57Z","timestamp":1758632517000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/msystems.00438-25"}},"subtitle":[],"editor":[{"given":"Babak","family":"Momeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":63,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,23]]}},"alternative-id":["10.1128\/msystems.00438-25"],"URL":"https:\/\/doi.org\/10.1128\/msystems.00438-25","relation":{},"ISSN":["2379-5077"],"issn-type":[{"value":"2379-5077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,23]]},"assertion":[{"value":"2025-03-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00438-25"}}